Intravacc, Primrose to advance conjugate vaccine development
29 Mar 2024
Vaccine
Preview
Source: Pharmaceutical Technology
The collaboration will offer third parties with a unified solution for vaccine conjugation, manufacturing, and supply. Credit: Ground Picture / Shutterstock.com.
Contract development and manufacturing organisation (CDMO) Intravacc and biotechnology company Primrose Bio have announced a strategic collaboration aimed at bolstering the conjugate vaccine development and supply.
This collaboration is set to provide third parties with a comprehensive solution for vaccine conjugation, manufacturing, and supply, streamlining the process for developers.
Intravacc will provide its extensive technical capabilities, advanced facilities, and expertise in antigen conjugation process development, scale-up, and GMP production of conjugate vaccines.
This expertise is crucial in ensuring the quality and efficacy of vaccines as they progress from concept to commercialisation.
Intravacc CEO Dr Jan Groen said: “We are excited to announce our partnership with Primrose Bio. By combining our expertise with Primrose’s cutting-edge technologies, we aim to revolutionise the landscape of conjugate vaccine development, ultimately benefiting millions worldwide.”
See Also:
ImmunoGen gets grant for method of preparing cell-binding agent-cytotoxic agent conjugate
Preview
Source: Pharmaceutical Technology
ReAlta signs deal with NIAID to develop drug for radiation poisoning
Preview
Source: Pharmaceutical Technology
Primrose Bio will complement Intravacc’s offerings with its ultra-pure manufacturing, supply chain, and regulatory support for the PeliCRM197 carrier protein.
As a key component in conjugate vaccine formulations, PeliCRM197 is the only commercial CRM197 used in licenced vaccines and is available for purchase.
This carrier protein can be supplied in various quantities and grades, ranging from milligrams to kilograms, catering to both research and GMP applications.
The latest collaboration between the parties represents a strategic alignment with the potential to significantly advance vaccine development.
Primrose Bio CEO Dr Helge Zieler said: “Expanding the capability of our PeliCRM197 franchise with Intravacc now creates a full-service solution for our early-stage customers and partners needing vaccine conjugation development.
“With both companies having direct product experience in preclinical, manufacturing, and clinical development, the combined know-how of the two firms fills a gap that is needed by the vaccine industry as a whole.”
In October 2022, Intravacc received a contract worth $14.6m from the US National Institutes of Health (NIH) unit National Institute of Allergy and Infectious Diseases (NIAID)Infectious Diseases (NIAID) to develop a prophylactic intranasal vaccine against Neisseria gonorrhoeae (NG).
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.